Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents

European Journal of Medicinal Chemistry

Volumn 107, Issue , 2015, Pages 219-232

  Shaik, Jeelan Basha ^a   Palaka, Bhagath Kumar ^b   Penumala, Mohan ^a   Kotapati, Kasi Viswanath ^b   Devineni, Subba Rao ^c   Eadlapalli, Siddhartha ^a   Darla, M Manidhar ^c   Ampasala, Dinakara Rao ^b   Vadde, Ramakrishna ^a   Amooru, G Damu ^a  

^a YOGI VEMANA UNIVERSITY   (India)

^b PONDICHERRY UNIVERSITY   (India)

^c SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Acetylcholinesterase; ADMET; Alzheimer's disease; Antioxidant; Butyrylcholinesterase; Fused tricyclic coumarin; Molecular modeling study; Neuroprotection

Indexed keywords

8 FORMY 7 HYDROXY 4 METHYLCOUMARIN; 8 IMINO 4 METHYL 2 OXO N (1 PHENYLETHYL) 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; 8 IMINO 4 METHYL 9 (MORPHOLINOCARBONYL) 2H,8H PYRANO[2,3 F]CHROME 2 ONE; 8 IMINO 4 METHYL 9 (TETRAHYDRO 1H 1 PYRROLYLCARBONYL) 2H,8H PYRANO[2,3 F]CHROME 2 ONE; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; GALANTAMINE; HYMECROMONE; N (2 BROMOBENZYL) 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N (2 CHLOROBENZYL) 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N (2,4 DIMETHOXYBENZYL) 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N (3 BROMOBENZYL) 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N (3 CHLOROBENZYL) 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N DODECYL 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N SUBSTITUTED CYANO ACETAMIDE DERIVATIVE; N [4 (TERT BUTYL)BENZYL] 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 (2 NITROPHENYL) 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 BENZHYDRYL 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 BENZYL 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 CYCLOHEXYL 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 CYCLOPROPYL 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 ETHYL 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 [1 (4 METHOXYPHENYL)ETHYL] 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9 [2 (2 METHOXYPHENOXY)ETHYL] 8 IMINO 4 METHYL 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; N9,4 DIMETHYL 8 IMINO 2 OXO 2H,8H PYRANO[2,3 F]CHROMENE 9 CARBOXAMIDE; UNCLASSIFIED DRUG; ACETYLCHOLINESTERASE; ANTIOXIDANT; CHOLINESTERASE; HYDROGEN PEROXIDE; NEUROPROTECTIVE AGENT;

ADULT; ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CELL DEATH; CELL VIABILITY; CHOLINESTERASE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MODEL; MOUSE; NEUROPROTECTION; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; NEUROTOXICITY SYNDROMES; PRECLINICAL STUDY; PROCEDURES; SYNTHESIS;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BINDING SITES; BUTYRYLCHOLINESTERASE; CHEMISTRY TECHNIQUES, SYNTHETIC; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; COUMARINS; DRUG EVALUATION, PRECLINICAL; GALANTAMINE; HUMANS; HYDROGEN PEROXIDE; MALE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES;

EID: 84947265466     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.10.046     Document Type: Article

References (49)

1. W. Xing, Y. Fu, Z. Shi, D. Lu, H. Zhang, Y. Hu, Discovery of novel 2,6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors, Eur. J. Med. Chem. 63 (2013) 95-103.
2. M. Palmer, Neuroprotective therapeutics for Alzheimer's disease: progress and prospects, Trends Pharmacol. Sci. 32 (2011) 141-147.
3. M. Citron, Alzheimer's disease: strategies for disease modification, Nat. Rev. Drug Discov. 9 (2010) 387-398.
4. M. Bartolini, C. Bertucci, V. Cavrini, V. Andrisano, β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies, Biochem. Pharmacol. 65 (2003) 407-416.
5. N.C. Inestrosa, A. Alvarez, C.A. Perez, R.D. Moreno, M. Vicente, C. Linker, O.I. Casanueva, C. Soto, J. Garrido, Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme, Neuron 16 (1996) 881-891.
6. A. Castro, A. Martinez, Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease, Mini Rev. Med. Chem. 1 (2001) 267-272.
7. E. Giacobini, Cholinesterases: new roles in brain function and in Alzheimer's disease, Neurochem. Res. 28 (2003) 515-522.
8. M. Pera, A. Martinez-Otero, L. Colombo, M. Salmona, D. Ruiz-Molina, A. Badia, et al., Acetylcholinesterase as an amyloid enhancing factor in PrP82-146 aggregation process, Mol. Cell Neurosci. 40 (2009) 217-224.
9. H. Soreq, S. Seidman, Acetylcholinesterase e new roles for an old actor, Nat. Rev. Neurosci. 2 (2001) 294-302.
10. R.S. Li, X.B. Wang, X.J. Hu, L.Y. Kong, Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease, Bioorg. Med. Chem. Lett. 23 (2013), 2636-264.
11. R.M. Lane, S.G. Potkin, A. Enz, Targeting acetylcholinesterase and butyrylcholinesterase in dementia, Int. J. Neuropsychopharmacol. 9 (2005) 1-24.
12. D.R. Liston, J.A. Nielsen, A. Villalobos, D. Chapin, S.B. Jones, S.T. Hubbard, I.A. Shalaby, A. Ramirez, D. Nason, W.F. White, Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease, Eur. J. Pharmacol. 486 (2004) 9-17.
13. M.A. Ansari, S.W. Scheff, Oxidative stress in the progression of Alzheimer disease in the frontal cortex, J. Neuropathol. Exp. Neurol. 69 (2010) 155-167.
14. R. Nunomura, X.J. Castellani, P.I. Zhu, G. Moreira, M.A. Perry, Smith, Involvement of oxidative stress in Alzheimer disease, J. Neuropathol. Exp. Neurol. 65 (2006) 631.
15. D.X. Tan, L.C. Manchester, R. Sainz, J.C. Mayo, F.L. Alvares, Antioxidant strategies in protection against neurodegenerative disorders, Expert Opin. Ther. Pat. 13 (2003) 1513-1543.
16. S. Thiratmatrakul, C. Yenjai, P. Waiwut, O. Vajragupta, P. Reubroycharoen, M. Tohda, C. Boonyarat, Synthesis, biological evaluation and molecular modeling study of novel Tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease, Eur. J. Med. Chem. 75 (2014) 21-30.
17. P. Anand, B. Singh, A review on cholinesterase inhibitors for Alzheimer's disease,, Archives Pharmacal Res. 36 (2013) 375-399.
18. P. Anand, B. Singh, N. Singh, A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease, Bioorg. Med. Chem. 20 (2012) 1175-1180.
19. L. Piazzi, A. Cavalli, F. Colizzi, F. Belluti, M. Bartolini, F. Mancini, M. Recanatini, V. Andrisano, A. Rampa, Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds, Bioorg. Med. Chem. Lett. 18 (2008) 423.
20. C. Garino, N. Pietrancosta, Y. Laras, V. Moret, A. Rolland, G. Quelever, J.L. Kraus, BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline, Bioorg. Med. Chem. Lett. 16 (2006) 1995.
21. D.D. Soto-Ortega, B.P. Murphy, F.J. Gonzalez-Velasquez, K.A. Wilson, F. Xie, Q. Wang, M.A. Moss, Inhibition of amyloid-β aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center, Bioorg. Med. Chem. 19 (2011) 2596.
22. C.A. Kontogiorgis, Y. Xu, D. Hadjipavlou-Litina, Y. Luo, Coumarin derivatives protection against ROS production in cellular models of Abeta toxicities, Free Radic. Res. 41 (2007) 1168.
23. B.Z. Kurt, I. Gazioglu, F. Sonmez, M. Kucukislamoglu, Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives, Bioorg. Chem. 59 (2015) 80-90.
24. M. Alipour, M. Khoobi, A. Moradi, H. Nadri, F.H. Moghadam, S. Emami, Z. Hasanpour, A. Foroumadi, A. Shafiee, Synthesis and anti-cholinesterase activity of new 7- hydroxycoumarin derivatives, Eur. J. Med. Chem. 83 (2014) 536-544.
25. A. Asadipour, M. Alipour, M. Jafari, M. Khoobi, S. Emami, H. Nadri, A. Sakhteman, A. Moradi, V. Sheibani, F.H. Moghadam, A. Shafiee, A. Foroumadi, Novel coumarin-3 carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors, Eur. J. Med. Chem. 70 (2013) 623-630.
26. M. Catto, L. Pisani, F. Leonetti, O. Nicolotti, P. Pesce, A. Stefanachi, S. Cellamare, A. Carotti, Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase, Bioorg. Med. Chem. 21 (2013) 146-152.
27. M. Alipour, M. Khoobi, A. Foroumadi, H. Nadri, A. Moradi, A. Sakhteman, M. Ghandi, A. Shafiee, Novel coumarin derivatives bearing N-benzyl pyridinium moiety: potent and dual binding site acetylcholinesterase inhibitors, Bioorg. Med. Chem. 20 (2012) 7214-7222.
28. S.F. Razavi, M. Khoobi, H. Nadri, A. Sakhteman, A. Moradi, S. Emami, A. Foroumadi, A. Shafiee, Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors, Eur. J. Med. Chem. 64 (2013) 252-259.
29. M. Khoobi, M. Alipour, A. Moradi, A. Sakhteman, H. Nadri, S.F. Razavi, M. Ghandi, A. Foroumadi, A. Shafiee, Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3′,4′:5,6]pyrano [2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase, Eur. J. Med. Chem. 68 (2013) 291-300.
30. L. Piazzi, A. Cavalli, F. Colizzi, F. Belluti, M. Bartolini, F. Mancini, et al., Multitarget-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds, Bioorg. Med. Chem. Lett. 18 (2008) 423-426.
31. M. Khoobi, M. Alipour, A. Sakhteman, H. Nadri, A. Moradi, M. Ghandi, S. Emami, A. Foroumadi, A. Shafiee, Design, synthesis, biological evaluation and docking study of 5- oxo- 4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors, Eur. J. Med. Chem. 68 (2013) 260-269.
32. K. Wang, K. Nguyen, Y. Huang, A. Domling, Cyanoacetamide multicomponent reaction (I): parallel synthesis of cyanoacetamides, J. Comb. Chem. 11 (2009) 920.
33. P. Tamiz, S.X. Cai, Z.L. Zhou, P.W. Yuen, R.M. Schelkun, E.R. Whittemore, E. Weber, R.M. Woodward, J.F.W. Keana, Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists, J. Med. Chem. 42 (1999) 3412.
34. H. Pechmann, C. Duisberg, Ber. die Verbindungen der Phenole mit Acetessigäther Dtsch, Chem. Ges. 16 (1883) 2119.
35. D.R. Bender, D. Kanne, J.D. Frazier, H. Rapoport, Synthesis and derivitization of 8- acetylpsoralens. Acetyl migrations during Claisen rearrangement, J. Org. Chem. 48 (1983) 2709-2719.
36. J. Volmajer, R. Toplak, I. Lebanb, A.M. Le Marechala, Synthesis of new iminocoumarins and their transformations into N-chloro and hydrazono compounds, Tetrahedron 61 (2005) 7012-7021.
37. G.L. Ellman, K.D. Courtney, V. Andres Jr., R.M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88-95.
38. H. Nadri, M. Pirali-Hamedani, M. Shekarchi, M. Abdollahi, V. Sheibani, M. Amanlou, et al., Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives, Bioorg. Med. Chem. 18 (2010) 6360-6366.
39. d+ radical cation assay, Free Radic. Res. 26 (1997) 195-199.
40. 2 induced DNA damage and repair in neuroblastoma cells, J. Homeop. Ayurv. Med. S1002 (2014) 1-5.
41. M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, et al., Free radicals and antioxidants in normal physiological functions and human disease, Int. J. Biochem. Cell Biol. 39 (2007) 44-84.
42. A. Rampa, F. Bisi, S. Belluti, P. Gobbi, V. Valenti, V. Andrisano, A. Cavrini, M. Cavalli, Recanatini, acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10- ylamine derivatives, Bioorg. Med. Chem. 8 (2000) 497-506.
43. Y. Bourne, et al., Conformational flexibility of the acetylcholinesterase tetramer suggested by X-ray crystallography, J. Biol. Chem. 43 (1999) 370-376.
44. R.A. Friesner, et al., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem. 47 (2004) 1739-1749.
45. Rapid ADME, QikProp, Version 3.5, Schrödinger, LLC, New York, NY, 2012.
46. H. Pajouhesh, G.R. Lenz, Medicinal chemical properties of successful central nervous system drugs, NeuroRx 4 (2005) 541-553.
47. D.E. Clark, S.D. Pickett, Computational methods for the prediction of 'drug-likeness', Drug. Discov. Today 2 (2000) 49-58.
48. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug. Deliv. Rev. 46 (2001) 3-26.
49. F. Hobbiger, R. Landaster, Determination of acetylcholinesterase activity of brain slices and its significance in studies of extracellular acetylcholinesterase, J. Neurochem. 18 (1971) 1741-1749.